Novo Nordisk Stock Up on Raised Price Target for Obesity Drug Success
• Analyst raised Novo Nordisk's price target by 16% to 930 Danish kroner based on success of obesity drug Wegovy
• Wegovy drove 36% sales growth in 2022, with obesity care revenue up 154%
• Competition coming from Eli Lilly's Mounjaro and Viking Therapeutics' weight loss drug
• Novo Nordisk stock closed nearly 4% higher on analyst's upgrade
• Motley Fool analysts identified 10 top stocks to buy now, not including Novo Nordisk